


Approximately what percentage of patients with acute myeloid leukemia (AML) have a FLT3 mutation?



Promising results have been observed with venetoclax in combination with which agent(s) in patients with AML?



Which of the following is a potential symptom of the veno-occlusive disease (VOD) that has been associated with gemtuzumab ozogamicin?



Which of the following is not one of the anticipated side effects of CPX-351?



A 65-year-old man with relapsed/refractory AML and an IDH2 mutation is started on enasidenib and after 8 weeks calls to inform you of fever, shortness of breath and a rapid weight gain of 10 pounds. Upon seeing him in clinic, you observe a new leukocytosis and a new oxygen requirement. What would you recommend?

Discontinue enasidenib and initiate antibiotics for infection

3%



Discontinue enasidenib and assess for heart failure

16%



Continue enasidenib, begin corticosteroids and admit the patient for differentiation syndrome

20%



I am currently not confident answering this question

61%



Inotuzumab ozogamicin is a(n)...



Which of the following adverse events have been observed with blinatumomab?



Which of the following are common symptoms of the cytokine release syndrome that has been observed with chimeric antigen receptor T-cell therapy?

